Trial Profile
Safety and efficacy of Tocilizumab for the treatment of Systemic Juvenile Idiopathic Arthritis in children (German BIKER registry)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Jun 2019
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharma Europe; Roche
- 15 Jun 2019 Results (n=345) assessing systemic and polyarticular juvenile idiopathic arthritis presented at the 20th Annual Congress of the European League Against Rheumatism
- 09 Feb 2016 New trial record
- 11 Nov 2015 Results (n=193) presented at the 79th American College of Rheumatology and the 50th Annual Meeting of the Association of Rheumatology and Health Professionals